Capricor Insider Sells Shares Amid Stock Decline
Karen Krasney, EVP and General Counsel at Capricor Therapeutics (NASDAQ:CAPR), sold approximately $732,000 worth of shares following the exercise of stock options. The transaction involved selling all newly acquired shares immediately after purchase under a prearranged trading plan governed by Rule 10b5-1. This move reduced Krasney's direct ownership in Capricor to around 30,547 shares valued at approximately $929,000 as of June 25, 2026. Capricor has experienced a significant price drop this year despite posting over 200% gains in the previous twelve months. The company is currently unprofitable and relies heavily on clinical trial outcomes for its pipeline products to drive future growth. Capricor stated it has sufficient capital to fund operations through Q4 of 2027, but market volatility remains a concern due to the nature of biotech investments. The insider sale does not necessarily indicate negative sentiment about company performance or stock price direction since such transactions are often part of structured compensation plans. However, investors may be watching for upcoming catalysts that could influence Capricor's trajectory.
Tickers: $CAPR